A Phase 3 interventional study of Romosozumab and Alendronate in Postmenopausal Women With Osteoporosis, sponsored by Amgen. Completed at 317 sites in 42 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 2nd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 3rd registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
University of Aarhus · Sites in Denmark
Ages 50+ · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
Marmara University · Sites in Turkey
Ages 55–85 · Women only
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2012.
This study's enrollment of 4,093 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 4th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2012, is one of 18 in phase 3, and was the 21st registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.
In this trial, women were randomly assigned in a 1:1 ratio to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months. Randomization was stratified according to age (\<75 vs. ≥75 years). After completion of the double-blind treatment period, all the participants were to receive open-label weekly oral alendronate until the end of the trial, with blinding to the initial treatment assignment maintained.
The primary analysis was performed when clinical fracture events had been confirmed in at least 330 participants and all the participants had completed the month 24 visit. The study was to continue in an event-driven manner until at least 440 participants experienced a nonvertebral fracture or if the superiority of romosozumab was proven for nonvertebral fractures at the primary analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women who meet at least one of the following bone mineral density (BMD) and fracture criteria:
BMD T-score at the total hip or femoral neck of ≤ -2.50 and EITHER:
BMD T-score at the total hip or femoral neck of ≤ -2.00 and EITHER:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
Drug: Alendronate · Drug: Placebo to Romosozumab
Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
Biological: Romosozumab · Drug: Alendronate · Drug: Placebo to Alendronate
Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
Also known as: AMG 785, Evenity
Alendronate 70 mg tablet taken once a week
Also known as: Fosamax
Administered by subcutaneous injection once a month during the double-blind treatment phase.
Matching placebo tablet taken once a week during the double-blind treatment phase.
Percentage of Participants With New Vertebral Fractures Through Month 24
All fracture assessments were performed by blinded central imaging readers. New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.
Time frame: 24 months
Percentage of Participants With a Clinical Fracture at the Primary Analysis
All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Percentage of Participants With Any Fracture at the Primary Analysis
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.
Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.
Time frame: 24 months
Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis
Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.
Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Percentage of Participants With a Hip Fracture at the Primary Analysis
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
Time frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.
Time frame: 24 months
Percentage of Participants With a Clinical Fracture Through Month 24
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 24 months
Percentage of Participants With a Nonvertebral Fracture Through Month 24
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 24 months
Percentage of Participants With a Hip Fracture Through Month 24
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
Time frame: 24 months
Percentage of Participants With a Clinical Vertebral Fracture Through Month 24
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.
Time frame: 24 months
Percentage of Participants With a Clinical Fracture Through Month 12
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 12 months
Percentage of Participants With New Vertebral Fractures Through Month 12
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader.
Time frame: 12 months
Percentage of Participants With Any Fracture Through Month 12
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.
Time frame: 12 months
Percentage of Participants With a Nonvertebral Fracture Through Month 12
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 12 months
Percentage of Participants With a Hip Fracture Through Month 12
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
Time frame: 12 months
Percentage of Participants With a Major Osteoporotic Fracture Through Month 12
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 12 months
Percentage of Participants With a Clinical Vertebral Fracture Through Month 12
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.
Time frame: 12 months
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 24
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 24
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 24
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 12
Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 12
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 12
Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 36
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 36
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and month 36
The study was conducted at 270 centers in 41 countries globally from 04 May 2012 to 29 June 2017.
| Milestone | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Started | 2047 | 2046 |
| Received double-blind treatment | 2040 | 2038 |
| Completed double-blind period | 1823 | 1831 |
| Completed primary analysis period | 1576 | 1574 |
| Completed | 1503 | 1523 |
| Not completed | 544 | 523 |
| Withdrew: Withdrawal by subject | 276 | 290 |
| Withdrew: Death | 113 | 106 |
| Withdrew: Lost to follow-up | 54 | 40 |
| Withdrew: Adverse event | 45 | 45 |
| Withdrew: Other | 22 | 19 |
| Withdrew: Noncompliance | 16 | 15 |
| Withdrew: Requirement for alternative therapy | 8 | 3 |
| Withdrew: Protocol deviation | 4 | 3 |
| Withdrew: Ineligibility determined | 5 | 2 |
| Withdrew: Administrative decision | 1 | 0 |
All fracture assessments were performed by blinded central imaging readers. New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With New Vertebral Fractures Through Month 24 | 8.0 | 4.1 |
All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Clinical Fracture at the Primary Analysis | 13.0 | 9.7 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis | 10.6 | 8.7 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With Any Fracture at the Primary Analysis | 19.1 | 13.0 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24 | 9.2 | 4.8 |
Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis | 9.6 | 7.1 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Hip Fracture at the Primary Analysis | 3.2 | 2.0 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24 | 2.5 | 1.3 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Clinical Fracture Through Month 24 | 9.6 | 7.1 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Nonvertebral Fracture Through Month 24 | 7.8 | 6.3 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Hip Fracture Through Month 24 | 2.1 | 1.5 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Clinical Vertebral Fracture Through Month 24 | 2.1 | 0.9 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Clinical Fracture Through Month 12 | 5.4 | 3.9 |
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height. Incident vertebral fractures were confirmed by a second independent reader.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With New Vertebral Fractures Through Month 12 | 5.0 | 3.2 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With Any Fracture Through Month 12 | 9.2 | 6.5 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Nonvertebral Fracture Through Month 12 | 4.6 | 3.4 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Hip Fracture Through Month 12 | 1.1 | 0.7 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Major Osteoporotic Fracture Through Month 12 | 4.2 | 3.0 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.
| percentage of participants | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percentage of Participants With a Clinical Vertebral Fracture Through Month 12 | 0.9 | 0.5 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24 | 7.2 ± 0.2 | 15.3 ± 0.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24 | 3.5 ± 0.1 | 7.2 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24 | 2.3 ± 0.2 | 6.0 ± 0.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12 | 5.0 ± 0.1 | 13.7 ± 0.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12 | 2.8 ± 0.1 | 6.2 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12 | 1.7 ± 0.1 | 4.9 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36 | 7.8 ± 0.2 | 15.2 ± 0.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36 | 3.5 ± 0.1 | 7.2 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Alendronate/Alendronate | Romosozumab/Alendronate |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36 | 2.4 ± 0.2 | 6.0 ± 0.2 |
Collected over Double-blind treatment phase: 12 months. Overall study period: From first dose of study drug up to the end of study for participants who received at any open-label dose and up to the end of the double-blind period for participants who did not. The median duration of follow-up time was 36 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Period: Alendronate 70 mg QW | 22/2,014 (1.1%) | 278/2,014 (13.8%) | 1,190/2,014 (59.1%) |
| Double-blind Period: Romosozumab 210 mg QM | 30/2,040 (1.5%) | 262/2,040 (12.8%) | 1,112/2,040 (54.5%) |
| Overall Study: Alendronate / Alendronate | 103/2,014 (5.1%) | 638/2,014 (31.7%) | 1,498/2,014 (74.4%) |
| Overall Study: Romosozumab / Alendronate | 101/2,040 (5%) | 611/2,040 (30%) | 1,424/2,040 (69.8%) |
| Event | Double-blind Period: Alendronate 70 mg QW | Double-blind Period: Romosozumab 210 mg QM | Overall Study: Alendronate / Alendronate | Overall Study: Romosozumab / Alendronate |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 17/2014 | 16/2040 | 46/2014 | 54/2040 |
| Femur fractureInjury, poisoning and procedural complications | 12/2014 | 11/2040 | 51/2014 | 42/2040 |
| Femoral neck fractureInjury, poisoning and procedural complications | 12/2014 | 5/2040 | 31/2014 | 15/2040 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 10/2014 | 5/2040 | 29/2014 | 24/2040 |
| Cardiac failureCardiac disorders | 5/2014 | 5/2040 | 25/2014 | 18/2040 |
| DeathGeneral disorders | 2/2014 | 1/2040 | 21/2014 | 14/2040 |
| Urinary tract infectionInfections and infestations | 8/2014 | 8/2040 | 21/2014 | 21/2040 |
| Radius fractureInjury, poisoning and procedural complications | 12/2014 | 8/2040 | 20/2014 | 14/2040 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/2014 | 6/2040 | 11/2014 | 19/2040 |
| Cerebrovascular accidentNervous system disorders | 7/2014 | 6/2040 | 15/2014 | 19/2040 |
| Event | Double-blind Period: Alendronate 70 mg QW | Double-blind Period: Romosozumab 210 mg QM | Overall Study: Alendronate / Alendronate | Overall Study: Romosozumab / Alendronate |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 233/2014 | 217/2040 | 406/2014 | 388/2040 |
| Back painMusculoskeletal and connective tissue disorders | 221/2014 | 184/2040 | 395/2014 | 330/2040 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 193/2014 | 165/2040 | 380/2014 | 343/2040 |
| FallInjury, poisoning and procedural complications | 151/2014 | 127/2040 | 342/2014 | 287/2040 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 129/2014 | 121/2040 | 253/2014 | 230/2040 |
| Urinary tract infectionInfections and infestations | 128/2014 | 97/2040 | 244/2014 | 180/2040 |
| HypertensionVascular disorders | 130/2014 | 113/2040 | 232/2014 | 233/2040 |
| Upper respiratory tract infectionInfections and infestations | 132/2014 | 130/2040 | 226/2014 | 205/2040 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 111/2014 | 113/2040 | 206/2014 | 189/2040 |
| HeadacheNervous system disorders | 110/2014 | 106/2040 | 190/2014 | 163/2040 |
| Age, Continuous(years) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| Mean | 74.2 ± 7.5 | 74.4 ± 7.5 | 74.3 ± 7.5 |
| Sex: Female, Male(Participants) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| Female | 2047 | 2046 | 4093 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| Hispanic or Latino | 662 | 631 | 1293 |
| Not Hispanic or Latino | 1385 | 1415 | 2800 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 5 | 12 |
| Asian | 149 | 137 | 286 |
| Black or African American | 23 | 19 | 42 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| White | 1415 | 1447 | 2862 |
| Multiple | 4 | 2 | 6 |
| Other | 446 | 436 | 882 |
| Missing | 1 | 0 | 1 |
| Age Strata per Randomization(Participants) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| < 75 years | 976 | 973 | 1949 |
| ≥ 75 years | 1071 | 1073 | 2144 |
| Severe Vertebral Fracture(Participants) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| Presence | 1321 | 1369 | 2690 |
| Absence | 726 | 677 | 1403 |
| Total Hip Bone Mineral Density (BMD) T-score(Participants) | Alendronate/Alendronate | Romosozumab/Alendronate | Total |
|---|---|---|---|
| ≤ -2.5 | 1384 | 1356 | 2740 |
| > -2.5 | 662 | 690 | 1352 |
| Missing | 1 | 0 | 1 |
Showing the first 100 of 317 sites across 42 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2012 to primary completion in Feb 2017, 57 months.
Results were first posted in Dec 2018, 1 year 9 months after primary completion. A results delay was requested in Dec 2017.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 57 months is above that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab